Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Platform Evaluated for Yeast Infected Blood

By LabMedica International staff writers
Posted on 12 Mar 2012
A polymerase chain reaction (PCR) protocol has been optimized that will detect low numbers of yeasts in small volumes of simulated and clinical specimens.

An innovative microfluidic real-time PCR platform was evaluated for the diagnosis of invasive candidiasis and has the potential for full automation and rapid turnaround. More...


Scientists at Duke University Medical Center (Durham, NC, USA) selected samples from patients with positive blood cultures for species of Candida as well as many blood culture-negative controls. Of particular interest were 16 banked blood specimens suspected to harbor C. albicans DNA for comparative testing on conventional and microfluidic real-time PCR platforms. Each of the 16 PCR-tested blood specimens was collected within 24 hours of a specimen from the same patient that later became culture-positive for C. albicans.

Eleven and nine of 16 specimens from individual patients with culture-proven candidemia tested positive for C. albicans DNA by conventional and microfluidic real-time PCR, respectively, for a combined sensitivity of 94%. Using simulated specimens, the investigators optimized the extraction protocol to detect five colony-forming units (CFU) of C. albicans in 500 µL blood; however, testing low CFU in small blood volumes confirmed this procedure to be stochastic. This problem could be ameliorated by sampling at least 1.0 mL blood and/or performing multiple tests.

The digital microfluidic platform for real-time PCR, pioneered by Advanced Liquid Logic, Inc. (Research Triangle Park, NC, USA), has the potential to revolutionize the diagnosis of infectious diseases by offering rapid, automated, economical, and point-of-care detection of pathogenic DNA in clinical samples. The authors concluded that the ideal diagnostic PCR test should be minimally invasive, specific, and sensitive, provide early detection, and amenable to frequent testing. The assay should be effective with minimal sample sizes, and predictive of infection in the target population. It should allow quantification, identification of multiple pathogens, have a low cost, and not require special expertise to perform. They believe that the digital microfluidic real-time PCR platform is on track to satisfy all of these criteria.

Related Links:

Duke University Medical Center
Advanced Liquid Logic



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers identified eight new DNA pattern signatures that could help refine diagnostics and guide targeted therapy in breast cancer (image credit: 123RF)

Breast Cancer-Specific Signatures Link Genome Instability to Outcomes

Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.